LIB Therapeutics Sets $300 Monthly List Price for the Autoinjector Form of LEROCHOL® (lerodalcibep-liga), Lowering Costs and Expanding Access for Adults Living With High Cholesterol

CINCINNATI--(BUSINESS WIRE)--LIB Therapeutics, Inc. (LIB), a privately held biopharmaceutical company with a singular focus on helping high-risk patients achieve their cholesterol goals, today announced that the autoinjector for LEROCHOL® (lerodalcibep-liga) Injection 300 mg/1.2 mL, an antibody-mimetic Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitor, will launch in the United States in January 2027 at a list price, or wholesale acquisition cost (WAC), of $300 per month, the lowe